Inhibition of Intestinal Metabolism of the Antiviral Ester Prodrug bis(POC)-PMPA by Nature-Identical Fruit Extracts as a Strategy to Enhance Its Oral Absorption: An In Vitro Study
- 152 Downloads
Purpose. To explore the usefulness of fruit extracts as enhancers of the oral absorption of esterase-sensitive prodrugs.
Methods. Inhibition of esterase-mediated degradation by nature-identical fruit extracts was evaluated using 1) p-nitrophenylacetate (model substrate for esterase-activity) in rat intestinal homogenates and 2) bis(isopropyloxycarbonyloxymethyl)-(R)-9-[(2-phosphonomethoxy) propyl]adenine [bis(POC)-PMPA] (esterase-sensitive prodrug of the antiviral agent PMPA) in Caco-2 cell homogenates and in intestinal homogenates from rat, pig and man. Subsequently, transport of the ester prodrug was studied across Caco-2 monolayers in the presence or absence of fruit extracts.
Results. In homogenates from rat ileum, the esterase activity could be reduced significantly by the inclusion of fruit extracts (1%): the initial enzymatic degradation of p-nitrophenylacetate was inhibited by 77% (strawberry), 16% (passion fruit) and 57% (banana). A similar inhibition of bis(POC)-PMPA metabolism by fruit extracts was observed in intestinal homogenates from several species and in homogenates from Caco-2 cells. Transport of total PMPA across Caco-2 monolayers was enhanced 3-fold by co-incubation with strawberry extract (1%). The fraction of intact prodrug appearing in the acceptor compartment increased from virtually zero to 67%.
Conclusions. The results suggest that co-incubation with nature-identical fruit extracts might be useful as a strategy to enhance the transepithelial transport of esterase-sensitive prodrugs through inhibition of intracellular metabolism of the prodrug.
Unable to display preview. Download preview PDF.
- 1.J. Balzarini, T. Vahlenkamp, H. Egberink, K. Hartmann, M. Witvrouw, C. Pannecouque, P. Casara, J.-F. Navé, and E. De Clercq. Antiretroviral activities of acyclic nucleoside phosphonates [(9-(2-phosphonomethoxyethyl)adenine, 9-(2-phosphonomethoxyethyl)-guanine, (R)-9-(2-phosphonomethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice. Antimicrob. Agents Chemother. 41:611–616 (1997).Google Scholar
- 2.J.-P. Shaw, C. M. Sueoka, R. Oliyai, W. A. Lee, M. N. Arimilli, C. U. Kim, and K. C. Cundy. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-phosphonomethoxypropyl]adenine (PMPA) in dogs. Pharm. Res. 14:1824–1829 (1997).Google Scholar
- 3.L. Naesens, N. Bischofberger, P. Augustijns, P. Annaert, G. Van den Mooter, M. N. Arimilli, C. U. Kim, and E. De Clercq. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob. Agents Chemother. 42:1568–1573 (1998).Google Scholar
- 4.P. Annaert, R. Kinget, L. Naesens, E. De Clercq, and P. Augustijns. Transport, uptake and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonomethoxyethyl) adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharm. Res. 14:492–496 (1997).Google Scholar
- 5.C. H. Walker and M. I. Mackness. Esterases: problems of identification and classification. Biochem. Pharmacol. 32:3265–3269 (1983).Google Scholar
- 6.M. Gratzl, W. Nastainczyk, and D. Schwab. The spatial arrangement of esterases in the microsomal membrane. Cytobiologie 11:123–132 (1975).Google Scholar
- 7.F. M. Williams. Clinical significance of esterases in man. Clin. Pharmacokin. 10:392–403 (1985).Google Scholar
- 8.H. M. J. Leng and J. A. Syce. Characterization of pulmonary alveolar esterases of the primate cercopithecus pygerythrus. Pharm. Res. 14:203–207 (1997).Google Scholar
- 9.D. G. Bailey, J. D. Spence, C. Munoz, and J. M. O. Arnold. Interaction of citrus juices with felodipine and nifedipine. Lancet 337:268–269 (1991).Google Scholar
- 10.Y. Yoshigae, T. Imai, A. Horita, H. Matsukane, and M. Otagiri. Species difference in stereoselective hydrolase activity in intestinal mucosa. Pharm. Res. 15:626–631 (1998).Google Scholar
- 11.I. J. Hidalgo, T. J. Raub, and R. T. Borchardt. Characterisation of the man colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736–749 (1989).Google Scholar
- 12.P. Augustijns, P. Annaert, P. Heylen, G. Van den Mooter, and R. Kinget. Drug absorption studies of prodrug esters using the Caco-2 model: evaluation of ester hydrolysis and transepithelial transport. Int. J. Pharm. 166:45–53 (1998).Google Scholar
- 13.O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:265–275 (1951).Google Scholar
- 14.M. Inoue, M. Morikawa, M. Tsuboi, Y. Ito, and M. Sugiura. Comparative study of human intestinal and hepatic esterases as related to enzymatic properties and hydrolyzing activity for ester-type drugs. Jpn. J. Pharmacol. 30:529–535 (1980).Google Scholar
- 15.N. Mignet. Recherche de nouveaux groupements bioréversibles pour masquer les charges internucleosidiques des oligonucleotides antisens. Etude de l'environnement du phosphore internucleosidique le plus adapté à l'approche pro-oligonucleotide. Doctoral thesis, Université Montpellier II, Sciences et Techniques du Languedoc, France, 1996.Google Scholar